|
|
Volumn 3, Issue 6, 2001, Pages 747-750
|
|
Clinical trials update: Highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME
a
a
|
|
Author keywords
Cardiology; ESCAMI; Heart failure; PAFAC; RITZ I; TIME; WARIS II
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTIANGINA PECTORIS AGENT;
ANTICOAGULANT AGENT;
ANTILIPEMIC AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
ENDOTHELIN RECEPTOR ANTAGONIST;
ENIPORIDE;
QUINIDINE;
SOTALOL;
TEZOSENTAN;
UNCLASSIFIED DRUG;
VERAPAMIL;
WARFARIN;
ACUTE HEART INFARCTION;
ADULT;
AGED;
ARTICLE;
CARDIOVERSION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CORONARY ARTERY DISEASE;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG SAFETY;
FEMALE;
HEART ATRIUM FIBRILLATION;
HEART FAILURE;
HEART PROTECTION;
HUMAN;
MALE;
MORTALITY;
MULTICENTER STUDY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
ANTICOAGULANTS;
ASPIRIN;
CARDIOVASCULAR DISEASES;
CLINICAL TRIALS, PHASE II;
ELECTRIC COUNTERSHOCK;
EUROPE;
GUANIDINES;
HUMANS;
PYRIDINES;
RANDOMIZED CONTROLLED TRIALS;
SULFONES;
TETRAZOLES;
VASODILATOR AGENTS;
WARFARIN;
|
|
EID: 0035202246
PISSN: 13889842
EISSN: None
Source Type: Journal
DOI: 10.1016/S1388-9842(01)00210-0 Document Type: Article |
|
Times cited : (74)
|
|
References (9)
|
